Par, Optimer CDAD deal

PRX will acquire 16% of Optimer (San Diego, Calif.) and will co-develop one of Optimer's antibiotics, now named PAR-101. The compound is in Phase IIa trials to treat C. difficile-associated diarrhea (CDAD) and has Fast Track designation. PAR-101 is expected to enter Phase IIb trials in the second half.

Under the deal, Optimer will fund all trial expenses of PAR-101, and PRX will be responsible for clinical development, regulatory, manufacturing and marketing. PRX has exclusive rights to the compound in the U.S. and Canada and will pay Optimer royalties. ...